Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP science news

Show

From To
Truvada as PrEP Tied to Only Modest Bone Density Decline

A new analysis also found a correlation between higher adherence to the daily drug regimen and greater bone density loss.

Published
17 June 2019
From
POZ
Study Suggests Widespread PrEP Use Would Take a Big Bite Out of HIV

The study also projected that PrEP use among adult gay and bi men would result in considerable reductions of HIV among adolescents.

Published
11 June 2019
From
POZ
Is Off-Label HIV Prevention Better Than None?

Rather than prescribe F/TDF as PrEP, Michael Saag, MD said, prescribers should sidestep the brand-name product and instead give their PrEP-eligible patients a generic HIV drug combination that uses lamivudine (3TC) with TDF.

Published
31 May 2019
From
MedPage Today (requires free registration)
New Zealand: The tide turns on HIV

The goal to virtually eliminate HIV transmission in NZ by 2025 suddenly looks attainable. Dr Peter Saxon explains why.

Published
17 May 2019
From
Newsroom
Some people may have genes that hamper a drug's HIV protection

Some people’s genes may stop an antiretroviral drug from protecting them against HIV, a genetics study suggests.

Published
13 May 2019
From
Science News
Do Feminizing Hormones Impact Efficacy of PrEP Drugs?

A team of investigators is examining why some transgender women taking hormones may need higher levels of PrEP medication.

Published
29 April 2019
From
Contagion Live
PrEP May Offer Psychological Benefits to Gay, Bisexual Men at Risk for HIV

A new study has identified lower rates of sexual anxiety among gay and bisexual men taking pre-exposure prophylaxis (PrEP).

Published
24 April 2019
From
American Journal of Managed Care
Letter to FDA Regarding Application for Descovy as Pre-Exposure Prophylaxis for HIV

TAG and PrEP4All sent this letter to Dr. Debra Birnkrant of the FDA, outlining and expressing our serious concerns about Gilead’s supplemental New Drug Application for Descovy (FTC/TAF) as HIV-1 preexposure prophylaxis (PrEP). There are several specific recommendations in the letter for this approval process, including recomending that the FDA convene a public meeting of the Antiviral Drug Advisory Committee.

Published
17 April 2019
From
Treatment Action Group
Sticker Shock: PrEP Is Not Cost-Effective at Current Price, Health Economists Find

For years, the U.S. HIV prevention community has known that pre-exposure prophylaxis (PrEP) is prohibitively expensive for many patients who need it. Now, new research presented at the 2019 National HIV Prevention Conference (NHPC) in Atlanta finds that not only is PrEP expensive for individual patients, it's also not cost-effective for the health system as a whole.

Published
09 April 2019
From
The Body
Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis

Filing Supported by Data Demonstrating Non-inferiority Compared to Truvada® Coupled with Bone and Renal Safety Advantages in People at Risk of Sexually Acquired HIV Infection

Published
08 April 2019
From
Gilead press release
← First123Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.